Fig. 5.
Compound 6 inhibits pancreatic tumor growth and reduces tumor vascular density. (A) Real-time fluorescent imaging of XPA-1-RFP pancreatic tumor xenografts in the pancreas of Nestin-GFP mice (n = 5/group) treated with either vehicle or 6 (50 mg/kg, i.p., bid). Drug treatments were started 3 days after surgical orthotopic implantation (SOI) of XPA-1-RFP tumors, and tumor progression was monitored every 3 days by whole-animal imaging. (Scale bar, 10 mm.) (B) Plot of tumor surface area over time for the vehicle- and 6-treated groups. Tumor surface area was calculated by adding the total pixels of both the ventral and lateral images of the tumor. *P = 0.034. (C) Average body weight of the mice measured each day of whole-animal imaging described in A and B. (D) Total weights of resected primary tumors on day 15 post-SOI. *P = 0.022. (E) Representative fluorescent images of endothelial GFP expression (GFP expression driven by the Nestin promoter) within the XPA-1-RFP tumors after resection. Images were taken 15 days post-SOI. (Scale bar, 200 μm.) (F) Plot of tumor vessel density from images acquired as in E. Blood vessels imaged as in E were converted to length (mm) and normalized to tumor volume (mm3). *P = 0.01.